FDA Reviews Drug-Eluting Stent Late Loss: More Than A Marketing Concept?

Late lumen loss should be regarded strictly in the context of drug-eluting stent safety, because its value as a surrogate measure of efficacy remains unclear, FDA cautions

More from Archive

More from Medtech Insight